4D Molecular Therapeutics, Inc. - FDMT
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Apr 07, 2026 | SCHEDULE 13G/A | JANUS HENDERSON GROUP PLC | 10.3% | 5,247,151 | View |
| Mar 26, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G | JANUS HENDERSON GROUP PLC | 8.1% | 4,635,875 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Novo Holdings A/S | 6.4% | 3,650,737 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 6.1% | 3,584,039 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 6.1% | 3,584,039 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 3.1% | 1,801,941 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 3.1% | 1,801,941 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.7% | 378,475 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.7% | 378,475 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 9.2% | 5,385,980 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 9.99% | 5,847,281 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF INC/IL | 9.99% | 5,847,281 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 9.99% | 5,847,281 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | RA Capital Management, L.P. | 9.9% | 5,713,852 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Peter Kolchinsky | 9.9% | 5,713,852 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Rajeev Shah | 9.9% | 5,713,852 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | RA Capital Healthcare Fund, L.P. | 9.9% | 5,713,852 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | THE GOLDMAN SACHS GROUP, INC. | 7.5% | 4,286,077 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | GOLDMAN SACHS & CO. LLC | 7.5% | 4,286,077 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.